Biomedicines 2021, 9(4)
Several other multi-agonists capable of co-agonism of the GLP-1 and glucagon receptors are currently in development including BI 456906 (Boehringer Ingelheim), LY3305677 (Lilly) LY4347943 (Lilly), JNJ-54729518 (J&J), HM15211 (Hanmi), NNC9204-1706 (Novo), Alt-801 (Altimmune) and G3215 (Imperial College/Zihipp Ltd.) see Table 1
If anything feels unusual, reach out to your healthcare provider
The difference is small, usually less than 1 unit, but on a 5-unit dose that represents up to 20% error
Unlike acute inflammation, it reflects a persistent, low-grade, non-resolving state that increases over time and is associated with age-related disease and mortality [10]
For optimal health and body composition, we want to decrease fat mass while maintaining and even increasing our lean muscle tissue